AHA Conference 2024 — New insights into the SUMMIT trial, investigating tirzepatide in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Milton Packer (Baylor Heart and Vascular Institute, US) to discuss the findings from the randomized, double-blind, phase 3 SUMMIT trial (NCT04847557) investigating the safety and efficacy of tirzepatide (LY3298176) in patients with heart failure with preserved ejection fraction and obesity. 731 participants were enrolled in the trial and were randomized 1:1 to recieve either tirzepatide or placebo.

Early announced findings have shown positive results, as the trial met its primary endpoint for safety and efficacy through 2 years, as well as better quality of life at one year.

Recorded onsite at AHA in Chicago, 2024.

Editors: Jordan Rance and Yazmin Sadik.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe CVRM.